BioSpace
Replimune’s resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug’s first two rejections.
BioSpace
Replimune's resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug's first two rejections.
BioSpace
Replimune’s resubmission for RP1 for melanoma comes after the departures of FDA leaders in place at the time of the drug’s first two rejections.